Significant Interaction

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Xiling Liu - One of the best experts on this subject based on the ideXlab platform.

  • absence of a Significant Interaction between a haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine
    Pediatric Infectious Disease Journal, 2000
    Co-Authors: Robert S Daum, Carol E Zenko, Gilbert Z Given, Gerard A Ballanco, Hemendra Parikh, Emmanuel Vidor, Xiling Liu
    Abstract:

    Background. We compared the antibody response to Haemophilus influenzae type b capsular polysaccharide (PRP) after three doses of a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (DTaP) combined with a PRP-tetanus conjugate (PRP-T) in infants randomized to receive oral polio vaccine (OPV) or inactivated polio vaccine (IPV). The polio vaccine was given separately at the same visit. Methods. Three hundred fifty-six infants from pediatric practices in suburban Chicago and New Orleans were randomized into two groups. Group A received OPV at 2 and 4 months of age; Group B received IPV at 2 and 4 months of age. Both groups received DTaP/PRP-T at 2, 4 and 6 months of age and hepatitis B vaccine at 2 and 4 months of age. A serum sample was obtained before immunization (age 2 months) and 1 month after 3 doses of DTaP/PRP-T (age 7 months). Sera were assayed for antibody responses to all relevant vaccine antigens. Results. No Significant vaccine antigen interference was found when polio immunization was provided by IPV or OPV for anti-PRP, diphtheria, tetanus or pertussis antibodies. OPV recipients had a Significantly higher mean antibody response to serotype 1 (P = 0.03) and 2 (P = 0.0001) poliovirus. Conclusion. Whether polio immunization was accomplished with IPV or OPV did not Significantly influence the antibody responses in sera obtained at 7 months of age for anti-PRP, anti-diphtheria and anti-tetanus toxoid antibodies and antibodies to pertussis antigens, when DTaP/PRP-T was given in the primary series.

Simin Dashtikhavidaki - One of the best experts on this subject based on the ideXlab platform.

  • a probable clinically Significant Interaction between warfarin and cloxacillin three case reports
    European Journal of Clinical Pharmacology, 2013
    Co-Authors: Hossein Khalili, Naemeh Nikvarz, Farhad Najmeddin, Simin Dashtikhavidaki
    Abstract:

    Cases Three patients were admitted to the Imam Hospital, Tehran, Iran with a diagnosis of bacterial endocarditis. The patients had indications for valve replacement surgery and anticoagulant therapy. The administration of cloxacillin reduced the effect of warfarin, and subsequent increases in warfarin doses were unable to overcome this effect.

  • a probable clinically Significant Interaction between warfarin and cloxacillin three case reports
    European Journal of Clinical Pharmacology, 2013
    Co-Authors: Hossein Khalili, Naemeh Nikvarz, Farhad Najmeddin, Simin Dashtikhavidaki
    Abstract:

    Three patients were admitted to the Imam Hospital, Tehran, Iran with a diagnosis of bacterial endocarditis. The patients had indications for valve replacement surgery and anticoagulant therapy. The administration of cloxacillin reduced the effect of warfarin, and subsequent increases in warfarin doses were unable to overcome this effect. A decrease in warfarin anticoagulation effects was detected in our three patients following cloxacillin therapy for infective endocarditis. Penicillinase-resistant penicillins remain essential antibiotics in the treatment of severe infections caused by Staphylococcus aureus due to their bactericidal activity, safety, and cost. Thus, in situations where anticoagulants are indicated in patients with infective endocarditis, it would be better to replace warfarin with low-molecular-weight or unfractionated heparin.

Harvey D White - One of the best experts on this subject based on the ideXlab platform.

  • impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization insights from the trilogy acs trial
    American Heart Journal, 2014
    Co-Authors: Jan H Cornel, Magnus E Ohman, Benjamin Neely, Peter Clemmensen, Piyamitr Sritara, Dmitry Zamoryakhin, Paul W Armstrong, Dorairaj Prabhakaran, Harvey D White
    Abstract:

    Background To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without revascularization. Methods and Results A total of 7062 patients aged 12 reaction unit (PRU) measurements. Current smokers (n = 1566 [22%]) at baseline had fewer comorbidities compared with non-smokers; nearly half quit smoking during follow-up. Although median on-treatment PRU values were lower with prasugrel vs. clopidogrel, persistent smokers had lower serial PRU values in both treatment groups compared with non-smokers, with no differential Interaction of treatment response by smoking status. The frequency of cardiovascular death, myocardial infarction, or stroke in current smokers was Significantly lower with prasugrel (11.7%) vs. clopidogrel (18.6%), but there was no difference in non-smokers (13.8% vs. 13.7%), with Significant Interaction between treatment and baseline smoking status ( P = .0002). Bleeding events occurred more frequently in prasugrel-treated patients with no Significant Interaction between treatment and baseline smoking status. Conclusions Among medically managed ACS patients

Magnus E Ohman - One of the best experts on this subject based on the ideXlab platform.

  • impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization insights from the trilogy acs trial
    American Heart Journal, 2014
    Co-Authors: Jan H Cornel, Magnus E Ohman, Benjamin Neely, Peter Clemmensen, Piyamitr Sritara, Dmitry Zamoryakhin, Paul W Armstrong, Dorairaj Prabhakaran, Harvey D White
    Abstract:

    Background To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without revascularization. Methods and Results A total of 7062 patients aged 12 reaction unit (PRU) measurements. Current smokers (n = 1566 [22%]) at baseline had fewer comorbidities compared with non-smokers; nearly half quit smoking during follow-up. Although median on-treatment PRU values were lower with prasugrel vs. clopidogrel, persistent smokers had lower serial PRU values in both treatment groups compared with non-smokers, with no differential Interaction of treatment response by smoking status. The frequency of cardiovascular death, myocardial infarction, or stroke in current smokers was Significantly lower with prasugrel (11.7%) vs. clopidogrel (18.6%), but there was no difference in non-smokers (13.8% vs. 13.7%), with Significant Interaction between treatment and baseline smoking status ( P = .0002). Bleeding events occurred more frequently in prasugrel-treated patients with no Significant Interaction between treatment and baseline smoking status. Conclusions Among medically managed ACS patients

Robert S Daum - One of the best experts on this subject based on the ideXlab platform.

  • absence of a Significant Interaction between a haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine
    Pediatric Infectious Disease Journal, 2000
    Co-Authors: Robert S Daum, Carol E Zenko, Gilbert Z Given, Gerard A Ballanco, Hemendra Parikh, Emmanuel Vidor, Xiling Liu
    Abstract:

    Background. We compared the antibody response to Haemophilus influenzae type b capsular polysaccharide (PRP) after three doses of a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (DTaP) combined with a PRP-tetanus conjugate (PRP-T) in infants randomized to receive oral polio vaccine (OPV) or inactivated polio vaccine (IPV). The polio vaccine was given separately at the same visit. Methods. Three hundred fifty-six infants from pediatric practices in suburban Chicago and New Orleans were randomized into two groups. Group A received OPV at 2 and 4 months of age; Group B received IPV at 2 and 4 months of age. Both groups received DTaP/PRP-T at 2, 4 and 6 months of age and hepatitis B vaccine at 2 and 4 months of age. A serum sample was obtained before immunization (age 2 months) and 1 month after 3 doses of DTaP/PRP-T (age 7 months). Sera were assayed for antibody responses to all relevant vaccine antigens. Results. No Significant vaccine antigen interference was found when polio immunization was provided by IPV or OPV for anti-PRP, diphtheria, tetanus or pertussis antibodies. OPV recipients had a Significantly higher mean antibody response to serotype 1 (P = 0.03) and 2 (P = 0.0001) poliovirus. Conclusion. Whether polio immunization was accomplished with IPV or OPV did not Significantly influence the antibody responses in sera obtained at 7 months of age for anti-PRP, anti-diphtheria and anti-tetanus toxoid antibodies and antibodies to pertussis antigens, when DTaP/PRP-T was given in the primary series.